Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease

Yoon Suk Jung, JaeHee Cheon, Sung Pil Hong, Tae Il Kim, Won Ho Kim

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: To date, there have been no studies focusing on the efficacy of thiopurine therapy in intestinal Behcet's disease (BD). We conducted this study to investigate clinical outcomes and predictors of clinical relapse in intestinal BD patients receiving thiopurine maintenance therapy. Methods: We reviewed the medical records of all patients with intestinal BD who received thiopurine therapy in a single tertiary academic medical center between March 1986 and October 2010. The cumulative probabilities of clinical relapse after remission were calculated using the Kaplan-Meier method. Predictors of clinical relapse were identified by univariate analysis using the log-rank test and by multivariate analysis using Cox proportional hazards regression models. Results: Of a total of 272 patients with intestinal BD, 67 (24.6%) received their first course of thiopurine therapy at our center. Thirty-nine (58.2%) of the 67 patients constantly received thiopurines for maintaining medically or surgically induced remission. The cumulative relapse rates at 1 year, 2 years, 3 years, and 5 years after remission were 5.8%, 28.7%, 43.7%, and 51.7%, respectively. On multivariate analysis, a younger age (<25 years) at diagnosis and a lower hemoglobin level (<11 g/dL) were independent predictive factors for relapse in intestinal BD patients receiving thiopurine maintenance therapy. Conclusions: Thiopurine therapy showed a relatively good effect for maintenance of remission in intestinal BD patients. However, a younger age at diagnosis and a lower hemoglobin level were associated with a poor response to thiopurines, necessitating early adoption of effective alternative therapeutic options in these risk groups.

Original languageEnglish
Pages (from-to)750-757
Number of pages8
JournalInflammatory Bowel Diseases
Volume18
Issue number4
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Intestinal Diseases
Behcet Syndrome
Recurrence
Therapeutics
Hemoglobins
Multivariate Analysis
Proportional Hazards Models
Medical Records
Maintenance

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Immunology and Allergy

Cite this

@article{739bff8602014399bd29c502238f37b2,
title = "Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease",
abstract = "Background: To date, there have been no studies focusing on the efficacy of thiopurine therapy in intestinal Behcet's disease (BD). We conducted this study to investigate clinical outcomes and predictors of clinical relapse in intestinal BD patients receiving thiopurine maintenance therapy. Methods: We reviewed the medical records of all patients with intestinal BD who received thiopurine therapy in a single tertiary academic medical center between March 1986 and October 2010. The cumulative probabilities of clinical relapse after remission were calculated using the Kaplan-Meier method. Predictors of clinical relapse were identified by univariate analysis using the log-rank test and by multivariate analysis using Cox proportional hazards regression models. Results: Of a total of 272 patients with intestinal BD, 67 (24.6{\%}) received their first course of thiopurine therapy at our center. Thirty-nine (58.2{\%}) of the 67 patients constantly received thiopurines for maintaining medically or surgically induced remission. The cumulative relapse rates at 1 year, 2 years, 3 years, and 5 years after remission were 5.8{\%}, 28.7{\%}, 43.7{\%}, and 51.7{\%}, respectively. On multivariate analysis, a younger age (<25 years) at diagnosis and a lower hemoglobin level (<11 g/dL) were independent predictive factors for relapse in intestinal BD patients receiving thiopurine maintenance therapy. Conclusions: Thiopurine therapy showed a relatively good effect for maintenance of remission in intestinal BD patients. However, a younger age at diagnosis and a lower hemoglobin level were associated with a poor response to thiopurines, necessitating early adoption of effective alternative therapeutic options in these risk groups.",
author = "Jung, {Yoon Suk} and JaeHee Cheon and Hong, {Sung Pil} and Kim, {Tae Il} and Kim, {Won Ho}",
year = "2012",
month = "4",
day = "1",
doi = "10.1002/ibd.21757",
language = "English",
volume = "18",
pages = "750--757",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease. / Jung, Yoon Suk; Cheon, JaeHee; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho.

In: Inflammatory Bowel Diseases, Vol. 18, No. 4, 01.04.2012, p. 750-757.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease

AU - Jung, Yoon Suk

AU - Cheon, JaeHee

AU - Hong, Sung Pil

AU - Kim, Tae Il

AU - Kim, Won Ho

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: To date, there have been no studies focusing on the efficacy of thiopurine therapy in intestinal Behcet's disease (BD). We conducted this study to investigate clinical outcomes and predictors of clinical relapse in intestinal BD patients receiving thiopurine maintenance therapy. Methods: We reviewed the medical records of all patients with intestinal BD who received thiopurine therapy in a single tertiary academic medical center between March 1986 and October 2010. The cumulative probabilities of clinical relapse after remission were calculated using the Kaplan-Meier method. Predictors of clinical relapse were identified by univariate analysis using the log-rank test and by multivariate analysis using Cox proportional hazards regression models. Results: Of a total of 272 patients with intestinal BD, 67 (24.6%) received their first course of thiopurine therapy at our center. Thirty-nine (58.2%) of the 67 patients constantly received thiopurines for maintaining medically or surgically induced remission. The cumulative relapse rates at 1 year, 2 years, 3 years, and 5 years after remission were 5.8%, 28.7%, 43.7%, and 51.7%, respectively. On multivariate analysis, a younger age (<25 years) at diagnosis and a lower hemoglobin level (<11 g/dL) were independent predictive factors for relapse in intestinal BD patients receiving thiopurine maintenance therapy. Conclusions: Thiopurine therapy showed a relatively good effect for maintenance of remission in intestinal BD patients. However, a younger age at diagnosis and a lower hemoglobin level were associated with a poor response to thiopurines, necessitating early adoption of effective alternative therapeutic options in these risk groups.

AB - Background: To date, there have been no studies focusing on the efficacy of thiopurine therapy in intestinal Behcet's disease (BD). We conducted this study to investigate clinical outcomes and predictors of clinical relapse in intestinal BD patients receiving thiopurine maintenance therapy. Methods: We reviewed the medical records of all patients with intestinal BD who received thiopurine therapy in a single tertiary academic medical center between March 1986 and October 2010. The cumulative probabilities of clinical relapse after remission were calculated using the Kaplan-Meier method. Predictors of clinical relapse were identified by univariate analysis using the log-rank test and by multivariate analysis using Cox proportional hazards regression models. Results: Of a total of 272 patients with intestinal BD, 67 (24.6%) received their first course of thiopurine therapy at our center. Thirty-nine (58.2%) of the 67 patients constantly received thiopurines for maintaining medically or surgically induced remission. The cumulative relapse rates at 1 year, 2 years, 3 years, and 5 years after remission were 5.8%, 28.7%, 43.7%, and 51.7%, respectively. On multivariate analysis, a younger age (<25 years) at diagnosis and a lower hemoglobin level (<11 g/dL) were independent predictive factors for relapse in intestinal BD patients receiving thiopurine maintenance therapy. Conclusions: Thiopurine therapy showed a relatively good effect for maintenance of remission in intestinal BD patients. However, a younger age at diagnosis and a lower hemoglobin level were associated with a poor response to thiopurines, necessitating early adoption of effective alternative therapeutic options in these risk groups.

UR - http://www.scopus.com/inward/record.url?scp=84858704854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858704854&partnerID=8YFLogxK

U2 - 10.1002/ibd.21757

DO - 10.1002/ibd.21757

M3 - Article

C2 - 21618352

AN - SCOPUS:84858704854

VL - 18

SP - 750

EP - 757

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 4

ER -